ルベル・インターナショナル病院
| トルコ | オーストリア | スペイン | |
| 免疫療法 | から $2,200 | から $30,000 | から $12,000 |
| 肺癌に対する免疫療法 | から $18,000 | から $30,000 | から $30,000 |
| 生物学的療法 | から $5,500 | から $20,000 | から $15,000 |
| 前立腺癌に対する免疫療法 | から $12,000 | から $30,000 | から $35,000 |
| 乳癌に対する免疫療法 | から $9,500 | から $35,000 | から $45,000 |
Bookimedは免疫療法価格に追加料金を加算しません。料金はクリニックの公式価格表から来ています。到着時にクリニックで免疫療法代を直接お支払いいただきます。
Bookimedはお客様の安全に取り組んでいます。免疫療法で高い国際基準を維持し、世界中の国際患者サービスに必要なライセンスを有する医療機関とのみ協力しています。
Bookimedは無料専門サポートを提供します。専属医療コーディネーターが治療前、治療中、治療後にサポートし、あらゆる問題を解決します。免疫療法の旅路でお一人になることはありません。
Dr. Lucía González Cortijo is a medical oncologist with more than 20 years of experience. She has led the Medical Oncology Department at Hospital Universitario Quirónsalud Madrid since 2020. Her focus areas include breast and gynecologic cancers. She also works in precision oncology, targeted therapies, and immunotherapy.
She has been Principal Investigator in more than 20 Phase II–III clinical trials. She has also served as sub-investigator in over 50 international trials. She previously worked at Quirónsalud Madrid from 2009 to 2020. Before that, she was at MD Anderson Cancer Center Madrid from 2002 to 2009.
She holds an MD and a PhD (cum laude) from the Autonomous University of Madrid. She completed her Medical Oncology specialty training at Hospital 12 de Octubre. She also earned a Master’s in Molecular Oncology. She is a member of SEOM, ESMO, ASCO, and GEICAM. She is a university lecturer.
Spain provides advanced immunotherapy options including checkpoint inhibitors, CAR T-cell therapy, and monoclonal antibodies. Leading centers like Centro Médico Teknon and Clínica Universidad de Navarra utilize biomarker-driven precision oncology to treat lung, breast, and hematologic cancers with drugs like Keytruda and Opdivo.
Bookimed Expert Insight: Spain stands out globally for institutional clinical trials. At Quironsalud Madrid, patients may qualify for free access to next-generation immunotherapy through active trials. Always confirm if your specific cancer markers, like PD-L1 or MSI, have been tested. These results often dictate which high-cost drugs clinics will approve for your case.
Patient Consensus: Patients recommend confirming the exact drug protocol and biomarker requirements early. Many highlight the importance of reporting immune-related side effects, such as fatigue or rashes, immediately to the clinical team.
Spain features internationally accredited institutions specialized in cutting-edge oncological care. Top hospitals for cancer immunotherapy include Clinica Universidad de Navarra, Centro Medico Teknon, and MD Anderson Cancer Center Madrid. These centers offer advanced checkpoint inhibitors, personalized biomarker matching, and access to international clinical trials.
Bookimed Expert Insight: Spain's oncology landscape is unique because private centers like Clinica Universidad de Navarra often lead in JCI certifications. However, our data shows institutional clusters in Madrid and Barcelona provide the best access to multidisciplinary tumor boards. For complex immunotherapy, look for clinics like Quironsalud Madrid that host over 20+ active Phase II and III trials.
Patient Consensus: Patients prioritize clinics with in-house molecular labs for PD-L1 testing and tumor board reviews. Many suggest visiting these reference centers in Madrid or Barcelona specifically for treatment planning before starting regimens.
International patients can access immunotherapy clinical trials in Spain through private centers and research hubs, though eligibility is determined on a case-by-case basis. Spain leads European oncology research, with clinics like Quironsalud Madrid offering free treatment for eligible participants in active Phase I-III studies.
Bookimed Expert Insight: While major centers like Quironsalud Barcelona and Teknon Medical Center serve thousands of international patients, trial success often depends on specialized units. For instance, Dr. Francesc Bosch at Quironsalud Barcelona currently manages over 80 Phase I-III trials. Patients should target institutions where principal investigators have a high volume of registration-enabling trials, as these clinics often have the most robust infrastructure for international enrollment and safety reporting.
Patient Consensus: Success depends on having a complete medical dossier ready, including translated pathology reports and specific biomarker panels like PD-L1 or MSI. Many find that early-phase trials are logistically difficult due to frequent monitoring, making later-phase studies more practical for those traveling from abroad.